Drugs / Ambrosia artemisiifolia allergen extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00770315 | Sep 2009 → May 2011 | allergic rhinitis, conjunctivitis | ALK-Abelló A/S | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ambrosia artemisiifolia allergen extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00770315 ↗ |
| Known as | Amb a 1-U | “This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced...” NCT00770315 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Ambrosia artemisiifolia allergen extract (Amb a 1-U)” NCT00770315 ↗ |
| Route | Other | “administered sublingually” NCT00770315 ↗ |